HiFiBiO: FibroGen Exercises Exclusive License Option for HiFiBiO's CCR8 Program

FibroGen, Inc. (Nasdaq: FGEN), a leading biopharmaceutical company discovering, developing, and commercializing first-in-class therapeutics, and HiFiBiO Therapeutics, a private, multinational clinical-stage biotherapeutics company with expertise in immune modulation and single cell science, today announced an extension of their partnership with FibroGen's exercise of an exclusive license option for HiFiBiO's anti-CCR8 monoclonal antibody program (HFB1011).